Latest Insider Transactions at Tff Pharmaceuticals, Inc. (TFFP)
This section provides a real-time view of insider transactions for Tff Pharmaceuticals, Inc. (TFFP). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of TFF Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of TFF Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 10
2021
|
Robert S Mills Director |
BUY
Exercise of conversion of derivative security
|
Direct |
700
+4.03%
|
$1,400
$2.5 P/Share
|
|
Jan 20
2021
|
Robert S Mills Director |
SELL
Open market or private sale
|
Direct |
12,600
-44.09%
|
$252,000
$20.2 P/Share
|
|
Jan 20
2021
|
Robert S Mills Director |
BUY
Exercise of conversion of derivative security
|
Direct |
12,600
+30.6%
|
$25,200
$2.5 P/Share
|
|
Jan 19
2021
|
Robert S Mills Director |
SELL
Open market or private sale
|
Direct |
55,100
-77.52%
|
$1,046,900
$19.56 P/Share
|
|
Jan 19
2021
|
Robert S Mills Director |
BUY
Exercise of conversion of derivative security
|
Direct |
55,100
+43.67%
|
$110,200
$2.5 P/Share
|
|
Jan 15
2021
|
Kirk Allen Coleman Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-83.33%
|
$85,000
$17.5 P/Share
|
|
Jan 15
2021
|
Kirk Allen Coleman Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+45.45%
|
$10,000
$2.5 P/Share
|
|
Jan 15
2021
|
Glenn R. Mattes President and CEO |
SELL
Open market or private sale
|
Direct |
40,000
-80.0%
|
$680,000
$17.51 P/Share
|
|
Jan 15
2021
|
Glenn R. Mattes President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+44.44%
|
$80,000
$2.5 P/Share
|
|
Dec 23
2020
|
Kirk Allen Coleman Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-90.91%
|
$150,000
$15.24 P/Share
|
|
Dec 23
2020
|
Kirk Allen Coleman Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+47.62%
|
$20,000
$2.5 P/Share
|
|
Dec 23
2020
|
Glenn R. Mattes President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-75.0%
|
$450,000
$15.33 P/Share
|
|
Dec 23
2020
|
Glenn R. Mattes President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+42.86%
|
$60,000
$2.5 P/Share
|
|
Dec 11
2020
|
Robert S Mills Director |
SELL
Open market or private sale
|
Direct |
22,794
-58.79%
|
$319,116
$14.58 P/Share
|
|
Dec 11
2020
|
Robert S Mills Director |
BUY
Exercise of conversion of derivative security
|
Direct |
22,794
+37.02%
|
$45,588
$2.5 P/Share
|
|
Dec 07
2020
|
James Brian Windsor Chief Science Officer |
SELL
Open market or private sale
|
Direct |
25,000
-83.33%
|
$375,000
$15.8 P/Share
|
|
Dec 07
2020
|
James Brian Windsor Chief Science Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+45.45%
|
$50,000
$2.5 P/Share
|
|
Dec 04
2020
|
Lung Therapeutics, Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,050,000
-9.63%
|
$13,650,000
$13.86 P/Share
|
|
Nov 24
2020
|
Aaron G.L. Fletcher Director |
BUY
Open market or private purchase
|
Direct |
5,000
+4.76%
|
$75,000
$15.13 P/Share
|
|
Nov 13
2020
|
Randy H Thurman Director |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$85,000
$17.17 P/Share
|
|
Nov 12
2020
|
Malcolm Fairbairn Director |
SELL
Open market or private sale
|
Indirect |
11,669
-100.0%
|
$175,035
$15.97 P/Share
|
|
Nov 11
2020
|
Randy H Thurman Director |
SELL
Open market or private sale
|
Direct |
34,504
-87.34%
|
$517,560
$15.91 P/Share
|
|
Nov 11
2020
|
Randy H Thurman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
34,504
+46.62%
|
$69,008
$2.5 P/Share
|
|
Nov 11
2020
|
Malcolm Fairbairn Director |
SELL
Open market or private sale
|
Indirect |
63,331
-84.44%
|
$949,965
$15.93 P/Share
|
|
Nov 11
2020
|
Stephen Rocamboli Director |
SELL
Open market or private sale
|
Direct |
15,722
-100.0%
|
$235,830
$15.76 P/Share
|
|
Nov 11
2020
|
Stephen Rocamboli Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,722
+50.0%
|
$31,444
$2.5 P/Share
|
|
Nov 10
2020
|
Glenn R. Mattes President and CEO |
SELL
Open market or private sale
|
Direct |
108,830
-91.58%
|
$1,523,620
$14.99 P/Share
|
|
Nov 10
2020
|
Glenn R. Mattes President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
108,830
+47.8%
|
$217,660
$2.5 P/Share
|
|
Nov 10
2020
|
Kirk Allen Coleman Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,000
-93.75%
|
$225,000
$15.12 P/Share
|
|
Nov 10
2020
|
Kirk Allen Coleman Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+48.39%
|
$30,000
$2.5 P/Share
|
|
Nov 10
2020
|
Stephen Rocamboli Director |
SELL
Open market or private sale
|
Direct |
21,278
-100.0%
|
$319,170
$15.14 P/Share
|
|
Nov 10
2020
|
Stephen Rocamboli Director |
BUY
Exercise of conversion of derivative security
|
Direct |
21,278
+50.0%
|
$42,556
$2.5 P/Share
|
|
Sep 25
2020
|
Glenn R. Mattes President and CEO |
SELL
Open market or private sale
|
Indirect |
3,000
-30.0%
|
$51,000
$17.0 P/Share
|